Hartree Partners’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Hartree Partners’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$7.49M	Buy	+750,000	New	+$7.3M	1.74%	15

Other funds holding EBAC

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Hartree Partners's EBAC Position: Q4 2021 in Review

Hartree Partners opened a new position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q4 2021: 750,000 shares worth $7.49M. The stake represents 1.74% of the portfolio and ranks #15 among its holdings.

45 funds tracked by Wall St. Rank hold EBAC as of Q4 2021.

Hartree Partners held 750,000 shares of European Biotech Acquisition Corp. Class A Ordinary Shares worth $7.49M as of Q4 2021.
European Biotech Acquisition Corp. Class A Ordinary Shares was a new Hartree Partners position in Q4 2021.
European Biotech Acquisition Corp. Class A Ordinary Shares made up 1.74% of Hartree Partners's portfolio in Q4 2021, its #15 holding.
45 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q4 2021.

Based on Hartree Partners's 13F filing for Q4 2021, filed 14 Feb 2022.